A5032843400- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Neurological Disorders and Treatments
- Aluminum toxicity and tolerance in plants and animals
- Renal Diseases and Glomerulopathies
- Congenital limb and hand anomalies
- Cardiovascular Disease and Adiposity
- Forensic Fingerprint Detection Methods
- Health and Well-being Studies
- Dermatological and COVID-19 studies
- Chronic Kidney Disease and Diabetes
- Systemic Sclerosis and Related Diseases
- Vitamin D Research Studies
- COVID-19 Clinical Research Studies
- Gastroesophageal reflux and treatments
- Long-Term Effects of COVID-19
- Cerebrovascular and Carotid Artery Diseases
- Renal and related cancers
- Renal and Vascular Pathologies
- Acute Myocardial Infarction Research
- Cardiovascular Function and Risk Factors
- Diabetes Management and Research
- Hemoglobinopathies and Related Disorders
- Neurological Disease Mechanisms and Treatments
- Cardiac Arrhythmias and Treatments
Hospital El Bierzo
1993-2024
Cardialysis (Netherlands)
2002
EuroEspes Biomedical Research Center
1998
Hospital de León
1993
Vitamin D status has been implicated in COVID-19 disease. The objective of the COVID-VIT-D trial was to investigate if an oral bolus cholecalciferol (100,000 IU) administered at hospital admission influences outcomes moderate-severe In same cohort, association between baseline serum calcidiol levels with also analysed.The is a multicentre, international, randomised, open label, clinical conducted throughout 1 year. Patients older than 18 years disease requiring hospitalisation were included....
Cytidine 5'-diphosphocholine (citicoline) is a an endogenous intermediate in the biosynthesis of structural membrane phospholipids and brain acetylcholine. Citicoline has been extensively used for treatment neurodegenerative disorders associated with head trauma, stroke, aging, cerebrovascular pathology Alzheimer's disease. In this study we have investigated efficacy safety citicoline versus placebo patients Alzheimer Thirty (age = 73.0 +/- 8.5 years; range 57-87 years) mild to moderate...
Aim: To analyze the frequency and variables related to inappropriate rivaroxaban dosage in clinical practice its impact on outcomes after 2 years. Materials & methods: Postauthorization, observational, multicenter study, which atrial fibrillation patients, treated with ≥6 months were included. Results: A total of 1421 patients (74.2 ± 9.7 years, CHA2DS2-VASc 3.5 1.6) Overall, 22.9% received 15 mg. The proper dose was taken by 83.3% (9.7% underdosed, 7.0% overdosed). Older age renal...
Although intravenous iron has proved to optimize the efficacy of EPOrHu in hemodialysis patients, hitherto no consensus exists with respect best regimen administration. We started a prospective randomized study 26 patients undergoing chronic who had adequate metabolism indices (serum ferritin >100 µg/l; %TSAT >20%; %HypoE <10% and CHr >26 pg) were maintenance phase administration (target hemoglobin obtained >10 g/dl). All receiving sodium ferric gluconate...
In order to control aluminium toxicity in dialysis patients it is preferable prevent or limit exposure it. However, sometimes necessary remove the by use of appropriate techniques. The collateral effects desferrioxamine have led us test new forms administering and attempt reduce dose. aim this study was compare removal administration 15 mg/kg under two different schemes, that is, 44 h before (classic scheme) 1 (new scheme). carried out 10 over a period 4 weeks. Aluminium quantified dialysate...